Quintrio
Home

SERVICES-SKILLED NURSING CARE FACILITIES

PACS Group, Inc.

PACS

PACS Group Inc is a post-acute healthcare company mainly focused on delivering skilled nursing care through a portfolio of independently operated facilities. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after getting discharged from the hospital. It also provides senior care, assisted living, and independent living options in some of the communities. The company has one reportable segment.

Last trade $48.40
Day change -$0.60 (-1.22%)
Day range $48.26 – $49.45
Volume 190,405
Market cap $7.78B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$7.78B
Price / earnings
28.02×
Price / book
6.41×
Price / sales
1.36×
EV / sales
1.39×
EV / EBITDA
15.95×

Profitability

Earnings per share
$1.75
Return on assets
4.69%
Return on equity
22.86%
Dividend yield
0.59%

Liquidity and leverage

Debt / equity
0.22×
Current ratio
0.8×
Quick ratio
0.8×
Cash ratio
0.1×

Cash flow

Price / cash flow
13.42×
Price / free cash flow
942.72×
Free cash flow
$8.25M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PACS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.5B$1.43B$1.42B$1.36B$1.34B$1.31B$1.28B$1.21B
Cost of revenue$1.14B$1.18B$1.07B$1.04B$1.05B$1.12B$1.02B$949.35M
Gross profit$356.43M$243.76M$345.96M$319.22M$298.31M$194.01M$253.36M$258.54M
Selling, general and administrative$138.41M$114.31M$112.32M$113.49M$102.53M$100.33M$98.72M$89.64M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$256.71M$134.43M$225.92M$224.53M$212.04M$113.51M$205.22M$186.56M
Operating income$99.72M$109.33M$120.04M$94.69M$86.27M$80.5M$48.14M$71.98M
Interest expense-$5.1M-$6.04M-$6.42M-$8.58M-$8.53M-$4.35M-$6.9M-$9.3M
Income before taxes$91.31M$105.84M$113.74M$86.81M$76.3M$78.61M$42.73M$61.2M
Income taxes$30.5M$29.49M$33.07M$27.03M$23.97M$27.65M$14.35M$25.01M
Net income$60.81M$76.35M$80.67M$59.79M$52.33M$50.97M$28.38M$36.19M
Net income attributable to common shareholders$60.82M$76.37M$80.7M$59.7M$52.41M$50.96M$28.47M$37.2M
EBITDA$119.8M$129.45M$138.11M$110.07M$100.67M$93.68M$60.85M$84.9M
Basic earnings per share$0.38$0.48$0.51$0.38$0.33$0.33$0.18$0.24
Diluted earnings per share$0.37$0.47$0.50$0.46$0.32$0.31$0.17$0.24

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

PACS Group, Inc. (PACS) Q3 Earnings and Revenues Beat Estimates

PACS Group, Inc. reported Q3 2026 earnings of $0.63 per share, beating consensus estimates of $0.56 and showing year-over-year growth from $0.32. Revenue reached $1.5 billion, surpassing estimates by 3.09%. The stock has gained 18.7% year-to-date, outperforming the S&P 500's 10.2% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates

Medpace (MEDP) reported Q3 2026 earnings of $4.84 per share, beating consensus estimates of $4.45, with revenues of $716 million exceeding expectations by 1.02%. However, the stock has underperformed the S&P 500 year-to-date, gaining 10.8% versus the market's 12.7%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical Services industry ranks in the bottom 34% of Zacks industries.

Zacks Investment Research

PACS Group, Inc. (PACS) Surges 6.2%: Is This an Indication of Further Gains?

PACS Group shares jumped 6.2% to $47.75 on investor optimism ahead of Q3 2026 earnings release. The company is expected to report 75% earnings growth and 8.1% revenue growth. However, with unchanged consensus EPS estimates over the past 30 days, analysts caution that the stock may lack momentum for sustained gains without positive estimate revisions.

Zacks Investment Research

PACS Expands Florida Footprint With 32-Facility Acquisition

PACS Group announced definitive agreements to acquire operations of 32 skilled nursing facilities across Florida with 4,049 licensed beds from Omega Healthcare Investors subsidiaries. The transaction, expected to close in Q4 2026, expands PACS's presence in the high-growth post-acute care market and establishes a statewide network in Florida. The acquisition complements PACS's existing Southern footprint across Texas, South Carolina, Tennessee, and Kentucky.

Zacks Investment Research

Here's Why Ensign Group Stock Remains a Buy for Investors

Ensign Group (ENSG) is benefiting from rising occupancy, patient volumes, and skilled-mix revenue growth in the post-acute care market. The company completed 25 acquisitions in H1 2026, adding 3,109 beds, and its Standard Bearer real estate segment generated $44.1 million in rental revenues. With a Zacks Rank #2 (Buy) rating and raised 2026 EPS guidance to $7.75-$7.85, ENSG faces headwinds from government reimbursement risks and rising expense growth.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.